Literature DB >> 1291405

Comparison of once-daily intravenous and oral omeprazole on pentagastrin-stimulated acid secretion in duodenal ulcer patients.

C Cederberg1, T Lind, K Röhss, L Olbe.   

Abstract

The effect of 5 days of once-daily dosing with 20 mg p.o. and 40 mg i.v. omeprazole on pentagastrin-stimulated acid secretion was studied in 8 patients with duodenal ulcer. In addition they also received a 10-mg i.v. dose on day 6 during the oral treatment period. The antisecretory effect was measured 6-7 h after dose at a time point when maximal inhibition during the dosing interval is anticipated. The median percent inhibition of peak acid output (PAO) markedly increased from 43% on day 1 to 100% on day 5 during treatment with 20 mg p.o. The first 40-mg i.v. dose produced a median inhibition of 98% of PAO already on day 1. After 5 days of dosing, the inhibition had increased to 100%. On the other hand, a 10-mg i.v. dose could essentially maintain the degree of PAO reduction reached after 5 days of oral treatment. Plasma omeprazole concentrations increased during repeated dosing both with 20 mg p.o. and 40 mg i.v.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1291405     DOI: 10.1159/000200992

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  6 in total

1.  Vonoprazan: MarKed Competition for PPIs?

Authors:  David R Scott; Elizabeth A Marcus; George Sachs
Journal:  Dig Dis Sci       Date:  2016-07       Impact factor: 3.199

Review 2.  Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.

Authors:  M I Wilde; D McTavish
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

3.  Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.

Authors:  K Ashida; Y Sakurai; A Nishimura; K Kudou; N Hiramatsu; E Umegaki; K Iwakiri; T Chiba
Journal:  Aliment Pharmacol Ther       Date:  2015-07-22       Impact factor: 8.171

4.  Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.

Authors:  Kiyoshi Ashida; Katsuhiko Iwakiri; Naoki Hiramatsu; Yuuichi Sakurai; Tetsuharu Hori; Kentarou Kudou; Akira Nishimura; Eiji Umegaki
Journal:  World J Gastroenterol       Date:  2018-04-14       Impact factor: 5.742

Review 5.  Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases.

Authors:  Tadayuki Oshima; Hiroto Miwa
Journal:  J Neurogastroenterol Motil       Date:  2018-07-30       Impact factor: 4.924

6.  Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans.

Authors:  M Katashima; K Yamamoto; Y Tokuma; T Hata; Y Sawada; T Iga
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jan-Mar       Impact factor: 2.569

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.